Drugs / RO7269162
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06733298 | Jan 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06402838 | May 2024 → Nov 2026 expected | Alzheimer disease | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7269162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06733298 ↗ |
| Route | Oral | “Following daily oral administration” NCT06402838 ↗ |